The Asian form is also suboptimal as a Western drug candidate because it comes from pig pancreases and the urine of young humans. Using animal or urine sources is not just aesthetically distasteful, it introduces risks of contamination into the production process that tend to put off regulators.
DiaMedica solved that problem by developing a proprietary, genetically modified cell type that expresses enormous amounts of KLK1 at a fraction of the cost of existing cell technologies. Big Pharma had tried to do this for years, always failing.
These cells have allowed DiaMedica to synthesize a drug under standardized conditions that has enormous potential—not only as treatments for many diseases, but as a breakthrough anti-aging geroprotector”
“Think of recombinant tissue kallikrein, DiaMedica’s lead product, as being a blood-vessel opening, blood-flow promoting substance that is nature’s preferred way of enhancing perfusion (flow) in tissues. You don’t have to be a rocket scientist to think of disease states where flow is aberrant or altered or needs assistance, right? What if recombinant tissue kallikrein had a role in all or many of those settings? Stroke, heart attack, peripheral vascular disease, angina, hypertension, maybe even PULMONARY hypertension.”
Recent DMAC News
- Form 8-K - Current report • Edgar (US Regulatory) • 08/07/2024 08:32:27 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/07/2024 08:31:01 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 07/19/2024 04:15:04 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 07/18/2024 09:28:35 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 07/10/2024 08:16:04 PM
- Form SC 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 07/08/2024 09:23:49 PM
- DiaMedica Therapeutics Announces Closing of $11.8 Million Private Placement • Business Wire • 07/01/2024 12:00:00 PM
- DiaMedica Therapeutics Announces $11.8 Million Private Placement • Business Wire • 06/26/2024 12:15:00 PM
- DiaMedica Therapeutics Announces Expansion of DM199 (Rinvecalinase Alfa) Program Into Preeclampsia • Business Wire • 06/26/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/03/2024 09:06:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/03/2024 08:59:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/03/2024 08:58:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/03/2024 08:41:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/03/2024 08:35:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/03/2024 08:29:48 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/03/2024 08:21:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/03/2024 08:14:56 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/03/2024 08:02:39 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 05/24/2024 08:01:48 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/23/2024 08:00:35 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/08/2024 08:34:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2024 08:30:55 PM
- DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2024 Financial Results • Business Wire • 05/08/2024 08:30:00 PM
- DiaMedica Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update May 9, 2024 • Business Wire • 05/02/2024 12:55:00 PM
- DiaMedica Therapeutics Announces First Patient Dosed in Relaunch of its Pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke • Business Wire • 04/17/2024 08:08:00 PM
FEATURED Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • Sep 24, 2024 8:50 AM
FEATURED Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM